Evidence map›Paper›PMID 22134222›Full record

ReviewCurrent opinion in gastroenterology2012

Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression.

Karen D Corbin, Steven H Zeisel

2 registry-linked trialsOpen access · greenAbstract readReview
In one paragraph

Review in Current opinion in gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 246 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
246citing papers in PubMed, 2 pooled it
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04302168 nacompletednot on this mapstarted 2020, after this paper: background citation

Effects of Choline Supplementation on Fetal Growth in Gestational Diabetes Mellitus

TypeinterventionalSponsorMaimonides Medical CenterRan2020 to 2024Enrolled46ConditionsGestational DiabetesArmsCholine supplement, Placebo
NCT05200156 naunknown statusnot on this mapstarted 2022, after this paper: background citation

The Impact Of Choline Administration On Oxidative Stress And Clinical Outcome Of Patients With Non-Alcoholic Fatty Liver Disease NAFLD

TypeinterventionalSponsorAin Shams UniversityRan2022 to 2024Enrolled100ConditionsNon-Alcoholic Fatty Liver DiseaseArmsPhosphatidyl Choline
3 · Its place in the literature

Who cites it

246 citing papers in PubMed, 2 syntheses or guidelines pooled it, 493 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Metabolomic profiles are reflective of hypoxia-induced insulin resistance during exercise in healthy young adult males.American journal of physiology. Regulatory, integrative and comparative physiology · 2021
    Trial
  6. Trial
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

186 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Karen D CorbinUniversity of North Carolina at Chapel Hill, Nutrition Research Institute, Kannapolis, North Carolina, USA.
Steven H Zeisel
David H. Murdock Research Institute · USUniversity of North Carolina at Chapel Hill · US

Funding

UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Stephanie Engel · 2001 to 2026
$36.3M
UNIV OF NORTH CAROLINA CLINICAL NUTRITION RESEARCH UNITP30DK056350 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Ian Michael Carroll · 1999 to 2026
$31.6M
HUMAN REQUIREMENTS FOR THE NUTRIENT CHOLINER01DK055865 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ZEISEL, STEVEN H · 2000 to 2011
$7.6M
NIDDK NIH HHS P30 DK056350NIDDK NIH HHS P30DK056350NIDDK NIH HHS R01 DK055865NIDDK NIH HHS R01 DK55865NIEHS NIH HHS P30 ES010126
6 · The paper itself

Abstract

purpose of reviewCholine is an essential nutrient and the liver is a central organ responsible for choline metabolism. Hepatosteatosis and liver cell death occur when humans are deprived of choline. In the last few years, there have been significant advances in our understanding of the mechanisms that influence choline requirements in humans and in our understanding of choline's effects on liver function. These advances are useful in elucidating why nonalcoholic fatty liver disease (NAFLD) occurs and progresses sometimes to hepatocarcinogenesis. RECENT

findingsHumans eating low-choline diets develop fatty liver and liver damage. This dietary requirement for choline is modulated by estrogen and by single-nucleotide polymorphisms in specific genes of choline and folate metabolism. The spectrum of choline's effects on liver range from steatosis to development of hepatocarcinomas, and several mechanisms for these effects have been identified. They include abnormal phospholipid synthesis, defects in lipoprotein secretion, oxidative damage caused by mitochondrial dysfunction, and endoplasmic reticulum stress. Furthermore, the hepatic steatosis phenotype can be characterized more fully via metabolomic signatures and is influenced by the gut microbiome. Importantly, the intricate connection between liver function, one-carbon metabolism, and energy metabolism is just beginning to be elucidated. SUMMARY: Choline influences liver function, and the dietary requirement for this nutrient varies depending on an individual's genotype and estrogen status. Understanding these individual differences is important for gastroenterologists seeking to understand why some individuals develop NAFLD and others do not, and why some patients tolerate total parenteral nutrition and others develop liver dysfunction.

Indexed as

AnimalsCholineDisease ProgressionFatty LiverHumansLiverMetabolic SyndromeNon-alcoholic Fatty Liver DiseaseCholine

Identifiers

PMID22134222
PMCPMC3601486
OpenAlexW2035588804

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.